SABCS 2020 | ASCENT: sacituzumab govitecan shows promise in mTNBC patients

Sara Hurvitz, MD, Ronald Reagan UCLA Medical Center, Los Angeles, CA, discusses the results of the ASCENT study (NCT02574455) aiming to evaluate the efficacy of sacituzumab govitecan, an anti-Trop-2 antibody-drug conjugate, versus standard of care chemotherapy in metastatic, triple-negative breast cancer (mTNBC) patients with a history of previous treatment. Trop-2 expression was measured and the participants were assessed for BRCA mutations to find any correlations with sacituzumab govitecan efficacy. Patients treated with sacituzumab govitecan had improved progression-free survival and overall survival rates compared to those treated with standard chemotherapy. The findings of this study show that sacituzumab govitecan treatment benefits all patient subgroups, regardless of Trop-2 expression levels or BRCA mutation status. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).